Salix Pharmaceuticals Ltd. (SLXP): Today's Featured Health Care Winner
Salix Pharmaceuticals (SLXP) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole was unchanged today. By the end of trading, Salix Pharmaceuticals rose $2.52 (5.1%) to $52.12 on heavy volume. Throughout the day, 1.7 million shares of Salix Pharmaceuticals exchanged hands as compared to its average daily volume of 889,900 shares. The stock ranged in a price between $50.48-$52.74 after having opened the day at $51.16 as compared to the previous trading day's close of $49.60. Other companies within the Health Care sector that increased today were: Arena Pharmaceuticals (ARNA), up 25.7%, Savient Pharmaceuticals (SVNT), up 16.7%, IsoRay (ISR), up 14%, and K-V Pharmaceutical Company (KV.B), up 11.7%. Salix Pharmaceuticals, Ltd. acquires, develops, and markets prescription drugs and medical devices used in the treatment of various gastrointestinal diseases in the United States. Salix Pharmaceuticals has a market cap of $2.81 billion and is part of the drugs industry. The company has a P/E ratio of 33.7, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 17.7. Shares are up 3.7% year to date as of the close of trading on Monday. Currently there are 11 analysts that rate Salix Pharmaceuticals a buy, no analysts rate it a sell, and five rate it a hold. TheStreet Ratings rates Salix Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.
- You can view the full Salix Ratings Report.
- Use our health care section to find sector-relevant news.
- Or find some new ideas from our top rated stocks lists.
- Find other investment ideas from our top rated ETFs lists.
Latest Headlines about SLXP
-
FDA Places New Heart-Safety Hurdle in Path of Opioid Constipation Drugs
10:31AM 11/12/12
-
Nektar Therapeutics Is a Short
07:08AM 09/12/12
-
Salix Pharmaceuticals' CEO Discusses Q2 2012 Results - Earnings Call Transcript
07:26PM 08/10/12
-
7 Most Reliable Growth Stocks in the Market
07:00AM 08/03/12
-
Stocks Take Breather After Recent Surge
04:41PM 07/30/12
-
5 Stocks Poised for Breakouts
01:32PM 02/28/12
-
Analysts' Actions: EXPE, WAG, UAL, RE
09:56AM 12/23/11
Latest from TheStreet Wire
-
SunPower Corporation (SPWR): Today's Featured Electronics Laggard
05:01PM 05/21/13
-
America Movil S.A.B. De C.V. (AMX): Today's Featured Technology Laggard
05:01PM 05/21/13
-
Urban Outfitters Inc. (URBN): Today's Featured Services Laggard
05:01PM 05/21/13
-
GameStop Corp (GME): Today's Featured Retail Laggard
05:01PM 05/21/13
-
Freeport-McMoRan Copper & Gold (FCX): Today's Featured Metals & Mining Laggard
05:01PM 05/21/13
-
Grupo Televisa S.A. (TV): Today's Featured Media Laggard
05:01PM 05/21/13
-
Salesforce.com Inc. (CRM): Today's Featured Computer Software & Services Laggard
05:01PM 05/21/13
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
